GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform

Generic drug user fees should only be considered in the context of changes to the Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA during a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet